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Induction of necroptosis in cancer stem cells by a nickel(II)-
dithiocarbamate phenanthroline complex 
Marie Flamme, Paul B. Cressey, Chunxin Lu, Peter M. Bruno, Arvin Eskandari, Michael T. Hemann, 
Graeme Hogarth, and Kogularamanan Suntharalingam* 
Abstract: The cytotoxic properties of a series of nickel(II)-
dithiocarbamate phenanthroline complexes is reported. The 
complexes, 1-6 kill bulk cancer cells and cancer stem cells (CSCs) 
with micromolar potency. Two of the complexes, 2 and 6 kill breast 
cancer stem cell (CSC)-enriched HMLER-shEcad cells 2-fold better 
than breast CSC-depleted HMLER cells. Complex 2 inhibits 
mammosphere formation to a similar extent as salinomycin (a CSC-
specific toxin). Detailed mechanistic studies suggest that 2 induces 
CSC death by necroptosis, a programmed form of necrosis. 
Specifically, 2 triggers MLKL phosphorylation, oligomerization and 
translocation to the cell membrane. Further, 2 induces necrosome-
mediated propidium iodide (PI) uptake and mitochondrial membrane 
depolarisation, and morphological changes consistent with 
necroptotosis. Strikingly, 2 does not evoke necroptosis by intracellular 
reactive oxygen species (ROS) production or poly ADP ribose 
polymerase (PARP-1) activation.  
Introduction 
Most compounds, including metal complexes, that have been 
investigated as anticancer agents induce cell death by 
programmed apoptosis and hence are susceptible to classical 
multi-drug resistance pathways.[1] Only a handful of metal 
complexes have been reported to induce cell death via non-
apoptotic pathways.[2] Characterized non-apoptotic pathways 
include autophagy, pyroptosis, ferroptosis, and necrosis.[3] 
Necrosis was originally thought to occur in a random, unregulated 
manner, however, recent studies have shown that it can proceed 
in an ordered fashion in certain cell types.[4] The most widely 
studied and major form of controlled necrosis is necroptosis.[5] 
Necroptosis hinges on the formation of an amyloid-like fibrillar 
complex called necrosome, consisting of receptor-interacting 
protein kinase 1 (RIP1), receptor-interacting protein kinase 3 
(RIP3), and mixed lineage kinase domain-like protein (MLKL).[6] 
The necrosome complex mediates downstream execution 
processes such as reactive oxygen species (ROS) burst, plasma 
membrane permeabilisation, mitochondrial membrane 
depolarisation, and bioenergetics depletion.[6b,7] As necroptosis 
utilizes protein components that are distinctly different from those 
used in apoptosis, cancer cells that display apoptosis resistance 
maybe be susceptible to necroptosis-inducers.[8]  
Multi-drug resistant pathways such as apoptosis 
dysfunction are operative in cancer stem cells (CSCs).[9] CSCs 
are a sub-population of tumor cells linked to cancer relapse and 
metastasis.[10] Due to their stem cell-like properties, CSCs divide 
in a slow and controlled manner, and thus evade conventional 
apoptosis-inducing chemotherapies which typically target fast 
growing cells.[11] Upon surviving initial treatment, CSCs are able 
to reform tumor masses and generate motile-proficient cancer 
cells capable of colonizing secondary tumor sites.[12] Therefore, 
cancer therapies must have the ability to eliminate entire tumor 
populations, including CSCs, to provide long-lasting durable 
responses. Potential CSC therapeutic targets, such as 
deregulated signaling pathways,[13] overactive organelles,[14] cell 
surface markers,[15] and vulnerable microenvironments[16] have 
been identified, however, there is still no clinically approved agent 
that can selectively remove CSCs. Apoptosis-resistant CSCs that 
possess the necessary protein machinery required for 
necroptotsis can be theoretically removed by necroptosis-
inducers.  
Platinum-based cancer drugs, cisplatin, carboplatin, and 
oxaliplatin, are widely used alone or in combination with other 
agents to treat various solid tumors, but they are ineffective 
against CSCs at their therapeutically administered doses.[17] Thus, 
alternative metal-based drugs with novel mechanisms of action 
are needed to overcome CSCs and prevent tumor reoccurrence. 
We and others have recently shown that copper, cobalt, gold, iron, 
and osmium complexes are able to potently and selectively kill 
CSCs (over bulk cancer cells).[17a,18] Small molecules containing 
nickel have been investigated as potential anticancer agents but 
detailed studies investigating their cellular mechanism of action 
are extremely rare and there have been no reports on their anti-
CSC properties.[19] Nickel(II) complexes containing 
semicarbazone and thiosemicarbazone ligands exhibit potent in 
vitro antiproliferative activity and are thought to induce their 
cytotoxic effect by damaging genomic DNA or inhibiting 
topoisomerase II.[20] Nickel(II)-tetraazamacrocyclic complexes 
also display promising in vitro activity against promyelocytic 
leukemia (HL-60) and hepatocellular carcinoma (BEL-7404) cell 
lines.[21] These complexes are thought to induce apoptotic cell 
death by condensing and clumping chromatin, and perturbing cell 
cycle progression. Nickel(II) complexes containing N-aroyl-N’-
thiohydrazide ligands inhibited Dalton’s lymphoma (DL) growth in 
vitro and prolonged survival of DL bearing mice, partly by 
reversing tumor associated immunosuppression.[22] More recent 
studies have shown that a nickel(II)-pyrithione complex is capable 
of inhibiting the proliferation of cultured tumor cells, primary cells 
from acute myeloid leukaemia human patients, and chronic 
myelogenous leukaemia (K562) and lung carcinoma (A549) 
xenografts in nude mice.[23] Detailed mechanistic studies suggest 
that the complex acts by inhibiting the ubiquitin-proteasome 
system (UPS) by targeting the 19S proteasome-associated 
deubiquitinases, UCHL5 and USP14. Herein we present the bulk 
cancer cell and CSC potency of a series of nickel(II)-
dithiocarbamate phenanthroline complexes, 1-6 and the novel 
necroptotic mechanism of action (in CSCs) of the 
diethyldithiocarbamate-bearing complex, 2.  
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Results and Discussion 
Synthesis, Characterization, and Stability in Solution 
The nickel(II)-dithiocarbamate phenanthroline complexes, 1-6 
investigated in this study are depicted in Figure 1. The nickel(II) 
complexes were prepared by reacting NiCl2•6H2O with two 
equivalence of the appropriate sodium dithiocarbamate in water 
to form the corresponding bis(N,N-dithiocarbamate)nickel(II) 
derivatives, 7 and 8 (Figure S1), followed by reaction of 7 or 8 with 
equimolar amounts of 1,10-phenanthroline, 3,4,7,8-tetramethyl-
1,10-phenanthroline, or 4,7-diphenyl-1,10-phenanthroline in 
acetone. The nickel(II) complexes, 1-6 were isolated in 
reasonable yields (44-89%) as dark green solids, and were fully 
characterized by UV-Vis and infra-red spectroscopy, and 
elemental analysis (see ESI). The spectroscopic data was fully 
consistent with previously reported data on nickel(II)-
dithiocarbamate phenanthroline complexes.[24] Attachment of the 
phenanthroline ligands was clearly illustrated by the 
hypsochromic shift of the broad d-d transition band from 635-640 
nm for 7 and 8 to ca. 605 nm for 1-6 (Figures S2). IR signals 
corresponding to C-N and C-S bonds (within the N,N-
dithiocarbamate moiety) displayed lower frequencies for 1-6 
compared to 7 and 8, further confirming binding of the 
phenanthroline ligands (see ESI).  
 
 
Figure 1. Chemical structures of the nickel(II)-dithiocarbamate phenanthroline 
complexes, 1-6 under investigation. 
 
The lipophilicity of the nickel(II)-complexes, 1-6 was 
determined by measuring the extent to which they partitioned 
between octanol and water, P. The experimentally determined 
LogP values for 1-6 varied between 0.83-2.71 (Table S1). The 
hydrophobic nature of the complexes suggests that 1-6 will be 
readily taken up by cells. UV-Vis and high-resolution ESI mass 
spectroscopy studies were carried out to assess the stability of 2, 
taken as a representative member of the nickel(II) series, in 
solution. NMR stability studies were not preformed given the 
paramagnetic nature of 2. The UV-Vis absorption of 2 (50 µM) in 
DMSO remained consistent over 24 h at 37 oC (Figure S3). Under 
these conditions, a peak corresponding to the molecular ion of 2 
with the appropriate isotopic distribution (534.0561 m/z) was 
observed in the positive mode of the ESI mass spectrum (Figure 
S4). In PBS:DMSO (300:1) containing whole cell lysate (5 x 103 
HMLER-shEcad cells) a marked decrease in the MLCT/LMCT 
absorption bands (> 300 nm) and a concurrent increase in the 
high energy band at 264 nm was observed (Figure S5), yielding a 
UV-Vis trace indicative of free 1,10-phenanthroline (Figure S6). 
Under these conditions, the molecular ion peak for 2 was not 
observed, however, a new ion peak corresponding to [1,10-
phenanthroline-H]+ (179.0197 m/z) appeared in the positive mode 
of the ESI mass spectrum (Figure S7). This suggests that 1,10-
phenanthroline is displaced from 2, possibly through interactions 
with nucleophilic biomolecules present in the cell lysate. Before 
carrying out cellular studies, the stability of 2 in mammary 
epithelial cell growth medium (MEGM) was assessed. In 
MEGM:DMSO (300:1),  2 (50 µM) is stable for up to 18 h at 37 oC 
(Figure S8). After 18 h, a marked decrease in absorption was 
observed (Figure S8). Upon incubation of 2 (50 µM) in MEGM for 
24 h at 37 oC, a new ion peak corresponding to [1,10-
phenanthroline-H]+ (179.0071 m/z) appeared in the positive mode 
of the ESI mass spectrum (Figure S9). This suggests that 1,10-
phenanthroline is displaced from 2 after prolonged incubation in 
MEGM. 
 
Cytotoxicity Against Cancer Cells and CSCs 
The anti-proliferative properties of 1-6 were initially assessed 
against a panel of human cancer cell lines (MDA-MB-231, HeLa, 
and U2OS cells) using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay. Cisplatin was included as a 
positive control. The IC50 values (concentrations required to 
reduce cell viability by 50%) were derived from dose-response 
curves (Figure S10-13) and are summarized in Table 1 and S2. 
Complexes 1-6 displayed micromolar toxicities, comparable to, 
and in some cases better than, that of cisplatin. Notably the IC50 
value of 6 is 11-fold lower against breast adenocarcinoma MDA-
MB-231 cells than the IC50 value of cisplatin. In general, 
complexes containing diethyldithiocarbamate (2, 4, and 6) 
displayed higher potency than the corresponding complexes with 
dimethyldithiocarbamate (1, 3, and 5). The cytotoxicity against 
breast CSC-enriched cells (HMLER-shEcad) and bulk breast 
cancer cells (HMLER) was also determined (Figure S14-15 and 
Table 1). All complexes displayed micromolar toxicity towards 
HMLER and HMLER-shEcad cells. Strikingly, the 
diethyldithiocarbamate-bearing complexes, 2 and 6 exhibited 2-
fold selective potency for CSCs over bulk cancer cells. This is 
comparable to salinomycin, a breast CSC-specific compound 
identified from a high-throughput screen (3-fold),[25] and a series 
of copper(II)–phenanthroline complexes containing nonsteroidal 
anti-inflammatory drugs (NSAIDs) recently reported by our group 
(3-fold).[18a,18c] Although salinomycin displays better potency and 
selectivity for CSCs than complex 2, complex 2 exhibits a 
significantly larger toxicity differential (the concentration 
difference between the IC50 values for HMLER and HMLER-
shEcad cells). 
 
Table 1. IC50 values of the nickel(II)-dithiocarbamate phenanthroline 
complexes, 1-6, cisplatin  and salinomycin against MDA-MB-231, HMLER cells, 
and HMLER-shEcad cells. 
Compound MDA-MB-231 
IC50 [μM] [a] 
HMLER 
 IC50 [μM] [a] 
HMLER-shEcad 
IC50 [μM] [a] 
1 41.4 ± 6.2  22.3 ± 6.2 25.2 ± 5.5 
2 10.9 ± 0.6 42.8 ± 4.3 21.6 ± 3.2 
3 20.1 ± 0.8  11.6 ± 0.7 32.8 ± 5.2 
4 7.8 ± 0.7 3.1 ± 0.3 6.0 ± 0.2 
5 5.7 ± 0.4 3.6 ± 0.1 5.0 ± 0.1 
6 3.3 ± 1.2 4.65 ± 0.2 2.3 ± 0.2 
cisplatin 36.6 ± 2.0 3.4 ± 0.5 [b] 4.9 ± 0.4 [b] 
salinomycin n.d. 16.4 ± 2.1 [b] 5.6 ± 0.1 [b] 
[a] Determined after 72 h incubation (mean of three independent experiments ± 
SD). [b] Reported in reference 18c. n.d. not determined. 
When breast CSCs are grown under low-attachment 
conditions in serum-free media, three-dimensional, tumour-like 
structures called mammospheres can be formed.[26] These 
structures provide a reliable in vitro model to probe CSC activity. 
The ability of 2 and 6 (the CSC-selective complexes) to inhibit 
HMLER-shEcad mammosphere formation from single cell 
    
 
 
 
 
suspensions at non-lethal doses was determined using an 
inverted microscope (Figure 2A-B). Dosage with 2 (at the IC20 
value after 5 days incubation) markedly reduced the number and 
size of mammospheres formed (Figure 2A-B). A similar result was 
previously observed for salinomycin.[18a] Treatment with 6 and 
cisplatin (at the IC20 value after 5 days incubation) did not 
significantly (p = 0.13 for 6 and p = 0.21 for cisplatin) reduce the 
number of mammospheres formed, however, the size of the 
mammospheres was noticeably reduced, albeit to a lesser extent 
than with 2 (Figure 2A-B). This data shows that 2 not only kills 
breast CSCs preferentially over bulk breast cancer cells, but also 
reduces mammosphere formation and growth. 
 
 
Figure 2. (A) Quantification of mammosphere formation with HMLER-shEcad 
cells untreated and treated with 2, 6, and cisplatin at their respective IC20 values 
for 5 days. Error bars = SD and Student t-test, * = p < 0.05. (B) Representative 
bright-field images (× 10) of the mammospheres in the absence and presence 
of 2, 6, and cisplatin, at their respective IC20 values. 
 
Cellular uptake by CSCs 
Cellular uptake studies were performed to elucidate the cell 
permeability of 1-6. HMLER-shEcad cells were incubated with 1-
6 (10 µM) for 24 h and the intracellular nickel content was 
determined by inductively coupled plasma mass spectrometry 
(ICP-MS). The complexes, 1-6 were readily internalized by cells, 
with whole cell uptake ranging from 575 ppb of Ni/ million cells for 
3 to 997 ppb of Ni/ million cells for 6 (Figure S16). A moderate 
correlation was observed between lipophilicity (LogP) and cell 
uptake. The 1,10-phenanthroline- and 3,4,7,8-tetramethyl-1,10-
phenanthroline-bearing complexes, 1-4, with Log P values 
ranging from 0.83-1.66, were internalized to a lesser extent than 
the 4,7-diphenyl-1,10-phenanthroline-containing complexes, 5 
and 6, with Log P values ranging from 2.12-2.71. Nickel(II) 
complexes containing diethyldithiocarbamate (2, 4, and 6) were 
taken up better than the corresponding complexes with 
dimethyldithiocarbamate (1, 3, and 5). A similar trend was also 
observed for HMLER-shEcad cell cytotoxicity (vide supra). Time 
dependent cellular uptake studies, over the course of 72 h, 
suggest that 2 is almost entirely taken up by HMLER-shEcad cells 
within 12 h of incubation (Figure S17).   
 
Mechanism of Action Studies 
To determine the mechanism of action of 2, the most effective 
anti-CSC complex based on monolayer and mammosphere 
studies, we utilized a mechanism of action predictive functional 
genetic assay based on RNAi.[27] This methodology relies on the 
response of eight murine lymphoma cell lines each harboring a 
distinct shRNA. Treatment of these cell lines with a compound of 
interest at equipotent concentrations, elicits a pattern of 
responses (or signature) that is unique to the mechanism of action 
of that given compound. Thus, when examining a new compound, 
one can compare its signature to those in the reference set, which 
includes nearly all classes of clinically used cytotoxins as well as 
more recently developed targeted therapeutics. When the RNAi 
signature of a given compound does not match any of the 
mechanism of action categories in the reference set, the relative 
similarities to compounds in the reference set, or those in the 
database but not in the reference set, can be used to gain insight 
into the mechanism of action. Using this approach, we found that 
the RNAi signature of 2 did not resemble any of the signatures in 
the reference set, and thus its mechanism of action was classified 
as a “new class” (Figure 3A). Next, we calculated the average of 
the absolute sum of the Euclidian distances between the RNAi 
signature of 2 and compounds not part of the reference set but in 
our database.  This analysis revealed similar signatures between 
2 and shikonin (Euclidian distance = 0.88, p-value = 0.11), a well-
established necroptosis inducer, and two rhenium(V)-oxo 
complexes (Euclidian distance = 1.51 and 1.91) previously 
characterized as ROS-inducing, necroptotic agents (Figure 
3A).[2d,28] Comparison of the Euclidian distances between the 
RNAi signature of 2 and those of previously reported metal-based 
CSC-selective agents[17a,18a-c] (Os-1, Cu-1-4, and Co-1, see 
Figure S18-19) revealed that their mechanisms of action were 
largely unrelated (Figure 3B). This was somewhat expected as 
Os-1, Cu-1-4, and Co-1 induce CSC death by apoptosis. A 
moderate correlation between the mechanism of action of 2 and 
Cu-1 was observed (Euclidian distance = 2.240). Overall the 
RNAi signature analysis suggests that 2 induces necroptosis and 
that its mechanism of action is distinct from other metal-based 
CSC-selective agents.  
To verify the mode of cell death evoked by 2, cytotoxicity 
studies were performed with HMLER-shEcad cells in the 
presence of necrosis and apoptosis inhibitors. Co-incubation of 2 
with IM-54 (10 µM), an inhibitor of unregulated necrosis mediated 
by oxidative stress,[29] did not significantly affect the toxicity of 2 
(p = 0.19) (Figure 3C), indicating that 2 does not induce 
unregulated necrosis. Distinct from unregulated necrosis, 
necroptosis, is a highly ordered form of necrosis that relies on the 
formation of necrosomes which initiate cell death. Necroptosis is 
inhibited by necrostatin-1 and dabrafenib, small molecule 
inhibitors of RIP1 and RIP3 respectively.[30] Co-incubation of 2 
with necrostatin-1 (20 µM) or dabrafenib (10 µM), significantly (p 
< 0.01) decreased the toxicity of 2 against HMLER-shEcad cells 
(Figure 3C). A similar effect was also observed for shikonin in the 
presence of necrostatin-1 or dabrafenib (Figure S20). This 
suggests that 2 may induce necrosome-mediated necroptotic cell 
death. Immunoblotting studies showed that the necrosome 
components; RIP1, RIP3, and MLKL are expressed in HMLER-
shEcad cells, and that their expression levels remain largely 
unaltered upon treatment with 2 (10 - 20 µM for 72 h; Figure S21). 
This suggests that 2-induced necroptosis in HMLER-shEcad cells 
relies on RIP1-RIP3-MLKL association, and not on the expression 
levels of the individual protein kinases. Co-incubation of 2 with z-
VAD-FMK (5 µM), a potent inhibitor of caspase-dependent 
apoptosis,[31] slightly increased 2 potency towards HMLER-
shEcad cells (Figure 3C). This suggests that blocking apoptosis 
in CSCs enhances 2-induced cell death. Similar enhancements in 
potency in the presence of z-VAD-FMK have been reported for 
other necroptosis-inducing agents.[2d,32] As expected, the CSC 
potency of cisplatin, an established apoptosis-inducing agent, 
significantly decreased (p < 0.05) in the presence of z-VAD-FMK 
(Figure S22). Immunoblotting studies showed that the expression 
of proteins associated with apoptotic cell death, namely, cleaved 
caspases 3 and 7 did not increase in HMLER-shEcad cells treated 
*
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with 2 (10 - 20 µM for 72 h; Figure S21), providing further evidence 
for non-apoptotic cell death. Collectively, the cytotoxicity and 
immunoblotting data for 2 is consistent with the mechanism of 
action derived from the RNAi-based assay. 
 
 
Figure 3. (A) RNAi signatures derived from the treatment of Eμ-Mycp19arf−/− 
lymphoma cells with 2, shikonin, [ReO(OMe)(3,4,7,8-tetramethyl-1,10-
phenanthroline)Cl2], and [ReO(OMe)(4,7-diphenyl-1,10-phenanthroline)Cl2] 
(top to bottom) at the LD80−90 concentration for each compound. (B) Euclidian 
distances between the RNAi signatures of 2 and previously reported metal-
based CSC-selective agents. Red indicates correlation and green indicates no 
correlation. (C) Graphical representation of the IC50 values of 2 against HMLER-
shEcad cells in the absence and presence of IM-54 (10 μM), necrostatin-1 (20 
µM), dabrafenib (10 µM), or z-VAD-FMK (5 µM). Error bars represent standard 
deviations and Student t-test, * = p < 0.01. 
 
Necroptosis Features in CSCs 
Recent studies have shown that necrosome formation triggers 
MLKL phosphorylation and homo-oligomerization.[6a,33] MLKL 
homo-oligomers can migrate from the cytoplasm to the cell 
membrane and induce ion flux, leading to plasma membrane 
permeabilization.[6a,33] MLKL phosphorylation and oligomerization 
was observed in HLMER-shEcad cells treated with 2 (10-20 µM 
for 72 h) (Figure S21). Immunoblotting analysis of the membrane 
and cytosol fractions of HMLER-shEcad cells treated with 2 (20-
40 µM for 24 h) indicated translocation of MLKL to the plasma 
membrane (Figure S23). To determine if 2 induces necrosome-
mediated, MLKL-induced plasma membrane permeabilization, 
propidium iodide (PI) staining studies were undertaken using flow 
cytometry. In the absence of permeabilization agents, PI 
accumulates in, and stains necrotic cells due to their 
compromised cell membranes. Cells undergoing early-stage 
apoptosis maintain their cell membrane integrity and thus are not 
stained by PI. HMLER-shEcad cells treated with 2 (40 µM for 24 
h) displayed increased PI uptake relative to untreated cells, 
suggestive of necrotic cell death (Figure 4A). A similar result was 
also observed for shikonin (100 nM for 24 h) dosed cells (Figure 
S23). In the presence of necrostatin-1 (20 µM), dabrafenib (10 
µM), or necrosulfonamide (2.5 µM, a small molecule inhibitor of 
MLKL oligomerization and migration)[34], 2- and shikonin-
mediated PI uptake was partially blocked (Figure 4A and S24). 
This suggests that 2-induced plasma membrane permeabilization 
is associated to necrosome formation and MLKL 
oligomerization/migration. Other morphological changes 
associated to necroptosis include cell volume expansion, 
increase in size of certain organelles, and preservation of the 
nuclear membrane. Microscopy studies with 2-treated (20 µM for 
24 h) HMLER-shEcad cells revealed a clear loss of plasma 
membrane integrity and intact nuclear membrane (Figure 4B and 
S25), consistent with necroptotic cell death.  
Necrosomes can induce cell death through mitochondrial 
membrane depolarization.[35] To determine the effect of 2 on the 
mitochondrial membrane potential, the JC-1 assay (5,5′,6,6′-
tetrachloro-1,1 ′ ,3,3 ′ -tetraethylbenzimidazolylcarbocyanine 
iodide) was employed. JC-1 is a membrane-permeable, cationic, 
lipophilic dye which accumulates in the mitochondria of healthy 
cells, forming red light emitting (ca. 590 nm) J-aggregates.[76] If 
the mitochondrial membrane is disrupted, JC-1 forms green light 
emitting (ca. 529 nm) monomers.[36] Therefore, mitochondrial 
depolarisation is indicated by a reduction in the red-green 
fluorescence intensity ratio. Upon incubation of HMLER-shEcad 
cells with 2 (20 µM for 24 h) a marked increase in the population 
of cells displaying mitochondrial membrane depolarisation was 
observed (Figure 4C and 4E). A similar trend was detected for 
HMLER-shEcad cells treated with carbonyl cyanide m-
chlorophenyl hydrazone (CCCP) (1 μM for 24 h), an established 
mitochondrial membrane depolarizer (Figure 4D). When 2 was 
co-incubated with necrostatin-1 (20 µM), mitochondrial 
membrane depolarisation was attenuated (Figure 4F), suggesting 
that 2-induced mitochondrial dysfunction is related to necrosome 
formation. 
 
 
Figure 4. (A) Representative histograms displaying the fluorescence emitted 
by PI stained HMLER-shEcad cells (red), and HMLER-shEcad cells treated with 
2 (40 µM for 24 h) (blue), 2 (40 µM for 24 h) with nectrostatin-1 (20 µM for 24 h) 
(orange), 2 (40 µM for 24 h) with dabrafenib (10 µM for 24 h) (light green), or 2 
(40 µM for 24 h) with necrosulfonamide (2.5 µM for 24 h) (dark green). (B) 
    
 
 
 
 
Representative bright-field image (× 40) of untreated HMLER-shEcad cells (top) 
and HMLER-shEcad cells treated with 2 (20 μM for 24 h) (bottom). (C) 
Representative 2D plots displaying the fluorescence emitted by JC-1 
aggregates (red) and JC-1 monomers (green) by untreated HMLER-shEcad 
cells, (D) HMLER-shEcad cells treated with CCCP (1 µM for 24 h), (E) HMLER-
shEcad cells treated with 2 (20 µM for 24 h), (F) HMLER-shEcad cells treated 
with 2 (20 µM for 24 h) and nectrostatin-1 (20 µM for 24 h). 
 
ROS- and PARP-Independent CSC Death 
Another feature of necrosome-mediated cell death is the 
generation of intracellular reactive oxygen species (ROS).[37] To 
determine if 2-induced cell death occurs via ROS production, 
intracellular ROS levels were quantified using 6-carboxy-2’,7’-
dichlorodihydrofluorescein diacetate (DCFH-DA), a well-
established ROS indicator. HMLER-shEcad cells treated with 2 
(40 µM for 6, 12, and 24 h) did not show a noticeable change in 
intracellular ROS levels compared to untreated cells (Figure S26). 
In contrast, H2O2 (150 µM for 6, 12, and 24 h) treated HMLER-
shEcad cells exhibited a significant increase (p < 0.05) in ROS 
levels, which was attenuated in the presence of N-acetylcysteine 
(2.5 mM, a ROS scavenger) (Figure S26). Taken together, this 
suggests that 2-induced cell death is not due to ROS generation 
and moreover, the mechanism of action of 2 does not involve 
necrosome-mediated ROS. 
Hyperactivation of PARP-1, a chromatin-associated 
enzyme involved in DNA repair, can also trigger necroptosis.[38] 
DNA damage can activate PARP-1, leading to ATP and NAD 
depletion and bioenergetics mediated cell death. Necrosome 
formation is thought to be a potential intermediate step that 
follows PARP-1 activation.[39] To determine if PARP-1 activation 
plays a role in 2-induced cell death, cytotoxicity studies were 
conducted in the presence of PARP-1 inhibitors, veliparib (ABT-
888, 10 µM)[40] and 4-amino-1,8-naphthalimide (ANA, 10 µM).[41]  
A statistically significant decrease in the potency of 2 towards 
HMLER-shEcad cells in the presence of the PARP-1 inhibitors 
was not observed (p = 0.49 for ABT-888 and ANA increased 
potency) (Figure S27), implying that 2-induced cell death is 
independent of PARP-1 activity. As expected, the cytotoxicity of 
cisplatin, a PARP-1 activator,[42] was significantly (p < 0.05) 
reduced in the presence of ABT-888 and ANA (Figure S28). The 
cytotoxicity data is consistent with immunoblotting studies, which 
show that 2-treatment (10 - 20 µM for 72 h) did not upregulate 
phosphorylated H2AX (γH2AX), a canonical marker for DNA 
damage (Figure S21). 
Conclusions 
In summary, we report a series of nickel(II)-dithiocarbamate 
phenanthroline complexes, 1-6 with anticancer potential. 
Complex 2 and 6 display CSC-selective toxicity, and complex 2 
inhibits CSC mammosphere formation to a similar extent as 
salinomycin, and better than 6 and cisplatin. Mechanistic studies 
show that 2 induces necroptosis in breast CSCs by necrosome-
mediated cell membrane disruption and mitochondrial membrane 
depolarization. Morphological changes consistent with 
necroptosis were also observed in 2-treated CSCs. Interestingly, 
2 does not induce necroptosis by elevating intracellular ROS 
levels or PARP-1 activity. As apoptosis-inducing anticancer 
agents are widely used to treat cancer patients, the incidence of 
apoptosis resistance in tumors is becoming more prevalent. 
Apoptosis resistance is also a hallmark of CSCs. Therefore, 
compounds such as 2, which can evoke cell death via novel non-
apoptotic pathways could hold the key to overcoming apoptosis 
resistant CSCs. Given that several metal complexes exhibit 
toxicity in the micromolar range, the anticancer credibility of these 
complexes including those presented here need to be validated 
in animal models. We aim to initiate in vivo studies with the 
nickel(II) complexes in the future. Overall, our findings could pave 
the way for the development of other non-apoptosis-inducing 
metal complexes for CSC-directed chemotherapy. 
Experimental Section 
Materials and Methods. All synthetic procedures were performed under 
normal atmospheric conditions. Fourier transform infrared (FTIR) spectra 
were recorded with a IRAffinity-1S Shimadzu spectrophotometer. UV-Vis 
absorption spectra were recorded on a Cary UV-vis spectrophotometer. 
Elemental analysis of the compounds prepared was performed 
commercially by London Metropolitan University. 1,10-Phenanthroline, 
3,4,7,8-tetramethyl-1,10-phenanthroline and 4,7-diphenyl-1,10-
phenanthroline were purchased from Sigma Aldrich and used as received. 
The bis(N,N-dithiocarbamate)nickel(II) derivatives, 7 and 8 were prepared 
used reported protocols.[43]  
 
Synthesis of Ni(N,N-dimethyldithiocarbamate)2(1,10-phenanthroline) 
(1): Bis(N,N-dimethyldithiocarbamate)nickel(II), 7 (48 mg, 0.16 mmol) was 
dissolved in acetone (5 mL) and added to 1,10-phenanthroline (29 mg, 
0.16 mmol). The solution was stirred at 50 oC for 3 h. The resulting 
precipitate was filtered, washed with acetone (10 mL) and water (10 mL), 
and dried. The isolated product was a dark green solid. (64 mg, 83%); UV 
(chloroform, nm): 387, 321, 289, 270, 248; IR (solid, cm-1): 2916, 2849, 
1716, 1493, 1424, 1373, 1338, 1249, 1222, 1197, 1125, 1049, 1024, 979, 
901, 850, 809, 781, 727, 722, 639, 577, 442; Anal. Calcd. for 1, 
C18H20N4NiS4 (%): C, 45.11; H, 4.21; N, 11.69. Found: C, 45.21; H, 3.96; 
N, 11.53. 
 
Synthesis of Ni(N,N-diethyldithiocarbamate)2(1,10-phenanthroline) 
(2): Bis(N,N-diethyldithiocarbamate)nickel(II), 8 (82 mg, 0.23 mmol) was 
dissolved in acetone (5 mL) and added to 1,10-phenanthroline (41 mg, 
0.23 mmol). The solution was stirred at 50 oC for 3 h. The resulting 
precipitate was filtered, washed with acetone (10 mL) and water (10 mL), 
and dried. The isolated product was a dark green solid. (69 mg, 57%); UV 
(chloroform, nm): 390, 325, 290, 270, 250; IR (solid, cm-1): 2968, 2930, 
1622, 1586, 1576, 1508, 1477, 1452, 1416, 1372, 1357, 1340, 1305, 1266, 
1210, 1135, 1067, 1050, 911, 866, 851, 811, 777, 729, 721, 638, 565; Anal. 
Calcd. for 2, C22H28N4NiS4 (%): C, 49.35; H, 5.27; N, 10.46. Found: C, 
49.18; H, 5.04; N, 10.41. 
 
Synthesis of Ni(N,N-dimethyldithiocarbamate)2(3,4,7,8-tetramethyl-
1,10-phenanthroline) (3): Bis(N,N-dimethyldithiocarbamate)nickel(II), 7 
(18 mg, 0.06 mmol) was dissolved in acetone (5 mL) and added to 3,4,7,8-
tetramethyl-1,10-phenanthroline (14 mg, 0.06 mmol). The solution was 
stirred at 50 oC for 3 h. The resulting precipitate was filtered, washed with 
acetone (10 mL) and water (10 mL), and dried. The isolated product was 
a dark green solid. (24 mg, 76%); UV (chloroform, nm): 396, 330, 276, 249; 
IR (solid, cm-1): 2920, 1499, 1426, 1370, 1256, 1241, 1128, 982, 886, 863, 
823, 729, 621, 571, 527, 448; Anal. Calcd. For 3, C22H28N4NiS4 (%): C, 
49.35; H, 5.27; N, 10.46. Found: C, 49.15; H, 5.26; N, 10.35.  
 
Synthesis of Ni(N,N-diethyldithiocarbamate)2(3,4,7,8-tetramethyl-
1,10-phenanthroline) (4): Bis(N,N-diethyldithiocarbamate)nickel(II), 8 (57 
mg, 0.16 mmol) was dissolved in acetone (5 mL) and added to 3,4,7,8-
tetramethyl-1,10-phenanthroline (38 mg, 0.16 mmol). The solution was 
stirred at 50 oC for 3 h. The resulting precipitate was filtered, washed with 
acetone (10 mL) and water (10 mL), and dried. The isolated product was 
a dark green solid. (42 mg, 44%); UV (chloroform, nm): 384, 319, 276, 250; 
IR (solid, cm-1): 2969, 2927, 1481, 1456, 1420, 1373, 1358, 1306, 1268, 
1241, 1212, 1139, 1075, 996, 914, 846, 815, 777, 724, 528; Anal. Calcd. 
for 4, C26H36N4NiS4 (%): C, 52.79; H, 6.13; N, 9.47. Found: C, 52.60; H, 
5.95; N, 9.32. 
 
    
 
 
 
 
Synthesis of Ni(N,N-dimethyldithiocarbamate)2(4,7-diphenyl-1,10-
phenanthroline) (5): Bis(N,N- dimethyldithiocarbamate)nickel(II), 7 (48 
mg, 0.16 mmol) was dissolved in acetone (5 mL) and added to 4,7-
diphenyl-1,10-phenanthroline (53 mg, 0.16 mmol). The solution was stirred 
at 50 oC for 3 h. The resulting precipitate was filtered, washed with acetone 
(10 mL) and water (10 mL), and dried. The isolated product was a dark 
green solid (90 mg, 89%); UV (chloroform, nm): 385, 314, 280, 251; IR 
(solid, cm-1): 1616, 1492, 1418, 1380, 1252, 1228, 1133, 979, 856, 832, 
797, 738, 711, 701, 630, 576, 547, 493, 445; Anal. Calcd. for 5, 
C30H28N4NiS4 (%): C, 57.06; H, 4.47; N, 8.87. Found: C, 56.81; H, 4.28; N, 
8.84. 
 
Synthesis of Ni(N,N-diethyldithiocarbamate)2(4,7-diphenyl-1,10-
phenanthroline) (6): Bis(N,N-diethyldithiocarbamate)nickel(II), 8 (60 mg, 
0.17 mmol) was dissolved in acetone (5 mL) and added to 4,7-diphenyl-
1,10-phenanthroline (57 mg, 0.17 mmol). The solution was stirred at 50 oC 
for 3 h. The resulting precipitate was filtered, washed with acetone (10 mL) 
and water (10 mL), and dried. The isolated product was a dark green solid. 
(61 mg, 52%); UV (chloroform, nm): 387, 317, 283, 250; IR (solid, cm-1): 
1617, 1559, 1476, 1416, 1355, 1263, 1209, 1134, 993, 910, 860, 769, 763, 
739, 702, 629, 575, 548; Anal. Calcd for 6, C34H36N4NiS4 (%): C, 59.39; H, 
5.28; N, 8.15. Found: C, 59.18; H, 5.64; N, 8.24. 
 
Measurement of Water-Octanol Partition Coefficient (Log P). The log 
P value for 1-6 was determined using the shake-flask method and UV-Vis 
spectroscopy. The octanol used in this experiment was pre-saturated with 
water. An aqueous solution of 1-6 (500 μL, 100 μM) was incubated with 
octanol (500 μL) in a 1.5 mL tube. The tube was shook at room 
temperature for 48 h. The two phases were separated by centrifugation 
and 1-6 content in each phase was determined by UV-Vis spectroscopy. 
 
Cell Lines and Cell Culture Conditions. U2OS bone osteosarcoma, 
MDA-MB-231 breast adenocarcinoma, and HeLa cervical 
adenocarcinoma cell lines were acquired from the American Type Culture 
Collection (ATCC, Manassas, VA, USA) and maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine 
serum and 1% penicillin/streptomycin. The human mammary epithelial cell 
lines, HMLER and HMLER-shEcad were kindly donated by Prof. R. A. 
Weinberg (Whitehead Institute, MIT). HMLER and HMLER-shEcad cells 
were maintained in Mammary Epithelial Cell Growth Medium (MEGM) with 
supplements and growth factors (BPE, hydrocortisone, hEGF, insulin, and 
gentamicin/amphotericin-B). The cells were grown at 310 K in a humidified 
atmosphere containing 5% CO2.  
 
Cytotoxicity MTT assay. The colourimetric MTT assay was used to 
determine the toxicity of 1-6. U2OS, MDA-MB-231, HeLa cells, HMLER, or 
HMLER-shEcad (5 × 103) were seeded in each well of a 96-well plate. After 
incubating the cells overnight, various concentrations of the compounds 
(0.2-100 µM), were added and incubated for 72 h (total volume 200 µL). 
Stock solutions of the compounds were prepared as 10 mM solutions in 
DMSO or PBS (cisplatin) and diluted using media. For compounds diluted 
from DMSO stock solutions, the final concentration of DMSO in each well 
was 0.5% and this amount was present in the untreated control as well. 
After 72 h, 20 μL of a 4 mg/mL solution of MTT in PBS was added to each 
well, and the plate was incubated for an additional 4 h. The DMEM/MTT or 
MEGM/MTT mixture was aspirated and 200 μL of DMSO was added to 
dissolve the resulting purple formazan crystals. The absorbance of the 
solutions in each well was read at 550 nm. Absorbance values were 
normalized to (DMSO-containing) control wells and plotted as 
concentration of test compound versus % cell viability. IC50 values were 
interpolated from the resulting dose dependent curves. The reported IC50 
values are the average of three independent experiments, each consisting 
of six replicates per concentration level (overall n = 18). 
 
Tumorsphere Formation and Viability Assay. HMLER-shEcad cells (5 
× 103) were plated in ultralow-attachment 96-well plates (Corning) and 
incubated in MEGM supplemented with B27 (Invitrogen), 20 ng/mL EGF, 
and 4 µg/mL heparin (Sigma) for 5 days. Studies were conducted in the 
absence and presence of 2, 6, and cisplatin. Mammospheres treated with 
2, 6, and cisplatin (at their respective IC20 values, 5 days) were counted 
and imaged using an inverted microscope.  
Cellular Uptake. To measure the cellular uptake of 1-6 ca. 1 million 
HMLER-shEcad cells were treated with 1-6 (10 μM) at 37 ºC for 3-72 h. 
After incubation, the media was removed, the cells were washed with PBS 
(2 mL × 3), harvested, and centrifuged. The cellular pellets were dissolved 
in 65% HNO3 (250 μL) overnight. The samples were diluted 5-fold with 
water and analysed using inductively coupled plasma mass spectrometry 
(ICP-MS, PerkinElmer NexION 350D). Nickel levels are expressed as Ni 
(ppb) per million cells. Results are presented as the mean of five 
determinations for each data point. 
 
RNAi Signatures. The nickel(II) complex, 2 was dosed to achieve an 
LD80-90 in Eμ-Mycp19arf-/- cells by propidium iodide exclusion as 
determined by flow cytometry after 48 h incubation. GFP 
enrichment/depletion was then determined by flow cytometry at 72 h. 
Linkage ratios (LR) and p-values were generated as described previously. 
All flow cytometry was conducted using a FACScan flow cytometer (BD 
Biosciences). Relatedness of 2 to other compounds in the database 
(including previously reported metal-based CSC-selective agents) was 
calculated by calculating the sum of the absolute differences of the 
Euclidian distances for each shRNA between the compounds. This can be 
represented by the following equation where C1 and C2 represent vectors 
of Compound 1 and Compound 2’s shRNA log2(RI) values: ∑ |C1 – C2|. 
 
GFP Competition Assays. Eμ-Mycp19arf-/- lymphoma cells were infected 
with GFP-tagged shRNAs such that 15-25% of the population were GFP 
positive. An eighth of a million cells in 250 μL B-cell media (BCM) were 
then seeded into 24-well plates. For wells that would remain untreated as 
a control, only 1/16th of a million cells were seeded. Next, 250 μL of media 
containing the active agent was added to the cells. After 24 h, 300 μL of 
cells from untreated wells are removed and replaced by 300 μL fresh BCM. 
All wells then received 500 μL BCM before being placed by in the incubator 
for another 24 h. At 48 h, cells transduced with the control vector, MLS, 
were checked for viability via flow cytometry on a FACScan flow cytometer 
(BD Biosciences) using propidium iodide as a live/dead marker. 
 
Immunoblotting Analysis. HMLER-shEcad cells (5 x 105 cells) were 
incubated with 2 (10, 15, and 20 μM for 72 h) at 37 oC. Cells were washed 
with PBS, scraped into SDS-PAGE loading buffer (64 mM Tris-HCl (pH 
6.8)/ 9.6% glycerol/ 2% SDS/ 5% β-mercaptoethanol/ 0.01% Bromophenol 
Blue), and incubated at 95 oC for 10 min. Whole cell lysates were resolved 
by 4-20 % sodium dodecylsulphate polyacylamide gel electrophoresis 
(SDS-PAGE; 200 V for 25 min) followed by electro transfer to 
polyvinylidene difluoride membrane, PVDF (350 mA for 1 h). Membranes 
were blocked in 5% (w/v) non-fat milk in PBST (PBS/0.1% Tween 20) and 
incubated with the appropriate primary antibodies (Cell Signalling 
Technology). After incubation with horseradish peroxidase-conjugated 
secondary antibodies (Cell Signalling Technology), immune complexes 
were detected with the ECL detection reagent (BioRad) and analysed 
using a chemiluminescence imager (Amersham Imager 600). 
 
Propidium Iodide (PI) Uptake. Untreated and treated HMLER-shEcad 
cells (1 × 106 cells/well) grown in six-well plates were washed with PBS (1 
mL × 3), harvested, incubated with PI (5 μM for 30 min), and analysed by 
using a FACSCanto II flow cytometer (BD Biosciences) (10,000 events per 
sample were acquired). The FL2 channel was used to assess intracellular 
PI uptake. Cell populations were analysed using the FlowJo software (Tree 
Star). 
 
JC-1 Assay. The JC-1 Mitochondrial Membrane Potential Assay Kit 
(Cayman) was used. The manufacturer’s protocol was followed to carry 
out this experiment. Untreated and treated HMLER-shEcad cells (1 × 106 
cells) grown in six-well plates were treated with the JC-1 staining solution 
for 30 min (100 μL/mL of cell media). Following staining, the cells were 
    
 
 
 
 
harvested, and analysed using a FACSCanto II flow cytometer (BD 
Biosciences) (10,000 events per sample were acquired). The FL1 and FL2 
channels were used to assess mitochondrial depolarisation. Cell 
populations were analysed using the FlowJo software (Tree Star). 
 
Intracellular ROS Assay. HMLER-shEcad cells (5 × 103) were seeded in 
each well of a 96-well plate. After incubating the cells overnight, they were 
treated with 2 or H2O2 (40 and 150 µM for 6, 12, and 24 h), in the presence 
or absence of N-acetylcysteine (2.5 mM), and incubated with 6-carboxy-
2′,7′-dichlorodihydrofluorescein diacetate (20 μM) for 30 min. The 
intracellular ROS level was determined by measuring the fluorescence of 
the solutions in each well at 529 nm (λex = 504 nm). 
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